Brokers Offer Predictions for GPCR FY2026 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for Structure Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will earn ($1.99) per share for the year. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03).

Several other analysts have also recently weighed in on the stock. William Blair started coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Citigroup started coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, HC Wainwright reduced their price objective on shares of Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $76.50.

Structure Therapeutics Stock Down 2.2%

Shares of Structure Therapeutics stock opened at $22.22 on Wednesday. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $53.45. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -30.03 and a beta of -1.87. The company’s fifty day moving average is $22.49 and its 200 day moving average is $24.76.

Institutional Trading of Structure Therapeutics

A number of institutional investors have recently bought and sold shares of GPCR. Deep Track Capital LP boosted its position in Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock valued at $75,936,000 after acquiring an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP boosted its position in Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after acquiring an additional 575,000 shares during the last quarter. Boxer Capital Management LLC bought a new stake in Structure Therapeutics during the fourth quarter valued at $13,560,000. Marshall Wace LLP boosted its position in shares of Structure Therapeutics by 339.6% during the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company’s stock worth $15,817,000 after purchasing an additional 450,531 shares in the last quarter. Finally, Foresite Capital Management VI LLC acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $11,390,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.